Markus Hosang is a General Partner and Managing Director at BioMedPartners. See sector focus and contact routes.
Markus Hosang is a General Partner and Managing Director at BioMedPartners, a Basel-based life sciences venture capital firm, where he joined in 2004 after nearly 20 years in senior Pharma R&D roles at Roche and a stint as Venture Partner at MPM Capital. His investment thesis targets early to mid-stage companies in biotechnology, pharmaceuticals, and medical technology, primarily within Switzerland and Europe. While specific check sizes for Hosang individually are not detailed, BioMedPartners manages approximately $400 million across more than 55 companies, often co-leading rounds such as the CHF 15 million Series A in ImmunOs Therapeutics. Notable portfolio companies include ImmunOs Therapeutics, which advanced a novel cancer immunotherapy into human trials with BioMedPartners as a co-lead investor. Hosang emphasizes that founders must have completed their homework, secured initial investments, and demonstrated a convincing business plan before he considers an investment. He has not published distinctive public writing or a unique point of view beyond these stated investment criteria in available interviews.
Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in Basel.
Investors like Markus Hosang · Full investor directory · Investor access · Company funding database